Nutropin AQ® (somatropin) NuSpin® will be commercially discontinued on December 31, 2024 in the United States. For more information, see here.
Select Safety for Pediatric Growth Hormone Deficiency (PGHD) patients:
Nutropin AQ (somatropin) therapy is indicated for the treatment of pediatric patients who have growth failure due to inadequate secretion of endogenous growth hormone (GH).
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
DRUG INTERACTIONS
USE IN SPECIFIC POPULATIONS
ADVERSE REACTIONS
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
Please see accompanying Nutropin full Prescribing Information for additional Important Safety Information.
CliniicalTrials.gov. A service of the U.S. National Institutes of Health. A Postmarketing Surveillance Program for Nutropin, Nutropin AQ®, and Protropin. Genentech. October 1985-July 2010.
CliniicalTrials.gov. A service of the U.S. National Institutes of Health. A Postmarketing Surveillance Program for Nutropin, Nutropin AQ®, and Protropin. Genentech. October 1985-July 2010.
Nutropin AQ® (somatropin) injection, for subcutaneous use. So. San Francisco, CA: Genentech, Inc; 2016.
Nutropin AQ® (somatropin) injection, for subcutaneous use. So. San Francisco, CA: Genentech, Inc; 2016.
Data on file. Genentech, Inc.
Data on file. Genentech, Inc.
Dook DM, Yuen KCJ, Biller BMK, et al. AACE Guidelines for use of growth hormone in clinical practice. Endocr Pract. 2009;15(Suppl 2), 1-29.
Dook DM, Yuen KCJ, Biller BMK, et al. AACE Guidelines for use of growth hormone in clinical practice. Endocr Pract. 2009;15(Suppl 2), 1-29.
Hokken-Koelega ACS, Saenger P, Cappa M, et al. Unresolved problems concerning optimal therapy of puberty in children with chronic renal diseases. J Pediatric Endocrinol Metab. 2001, Jul;14 Suppl2:945-952.
Hokken-Koelega ACS, Saenger P, Cappa M, et al. Unresolved problems concerning optimal therapy of puberty in children with chronic renal diseases. J Pediatric Endocrinol Metab. 2001, Jul;14 Suppl2:945-952.
Sebastian, a Nutropin patient, and his mom, Andrea, walk through the steps associated with using the NuSpin device for Nutropin therapy.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.